About Beta Bionics Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.betabionics.com
Frequently Asked Questions
What is the 52-week range for BBNX?
The 52-week high is $32.71 and the 52-week low is $8.8.
What is the P/E ratio for BBNX?
The P/E ratio data is currently unavailable.
What is the dividend yield for BBNX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -26.30%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -61.32%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.66.
Analyst Recommendation Trends
Wall Street analyst consensus for BBNX over the last few months:
Latest BBNX News
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.
Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2026 financial results after the financial markets close on Tuesday, October 27, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s third quarter 2026 performance. The
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $23 to $28.
Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28
Wells Fargo analyst Larry Biegelsen initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Overweight rating and announces Price Target of $28.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 0.5% and the St
Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) system. Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics exp
Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock
IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less th
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
BBNX's FDA-cleared Mint patch pump expands its diabetes portfolio, with a full U.S. launch planned for the first quarter of 2027.
Beta Bionics - Interesting & Uncertain Times
Beta Bionics stock outlook: Mint patch pump 2027 launch, $150M raise, lowered sales guidance and margin dilution risks. Click to read my analysis.
Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?
Beta Bionics, Inc. (BBNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Beta Bionics: Mint Clearance Marks The Shift Toward A Multi-Engine Growth Story
Beta Bionics (BBNX) outlook: Mint patch pump FDA-cleared for 1Q27, boosting diabetes platform growth despite 2026 deferral.
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures rose, but Beta Bionics fell 7.1% after pricing a stock offering; several other stocks also declined in premarket trading.
Beta Bionics (BBNX) Stock Sees Fair Value Lift As Analysts Reassess Pipeline Timing
Beta Bionics is drawing fresh attention after its fair value estimate and related analyst price target moved from about US$19.80 to roughly US$21.67. That shift lines up with recent Street research, where firms are reassessing the company’s pipeline, expected patch pump entry and the timing of Type 2 diabetes and fully closed loop indications before updating their targets. As you read on, you will see how to track this evolving narrative and what to watch as new information comes...
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less the $0.0001 exercise pri
Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock
IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125.0 million of shares of its common stock. All of the shares are being offered by Beta Bionics. In addition, Beta Bionics intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $18.75 million of the shares of its common stock offered in t
Beta Bionics Announces Proposed $125M Public Offering Of Common Stock
Beta Bionics, Inc. (NASDAQ:BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125.0 million of shares of its common stock. All of the
Truist Securities Reiterates Buy on Beta Bionics, Raises Price Target to $23
Truist Securities analyst Richard Newitter reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $22 to $23.
Baird Maintains Neutral on Beta Bionics, Raises Price Target to $16
Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $14 to $16.
Beta Bionics’ insulin patch pump gets FDA nod
By bringing its first patch pump to market, Beta Bionics will be able to compete with industry leader Insulet.
Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm
Mint features a new and innovative patch pump architecture Full Mint U.S. commercialization expected to begin in Q1 2027 Manufacturing capacity expected to produce at least 1.5 million disposable Mint units during 20273D Intelligence, the Company’s next-generation insulin dosing algorithm, has been submitted to the FDA through a 510(k) applicationExpectations to commercialize 3D Intelligence in the U.S. by the end of 2026 as iLet 3D™, and at the time of full Mint launch as Mint 3D™, subject to r
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world’s first and only long-term, one-year implantable sens
Beta Bionics Receives FDA Clearance For Its Mint Pump That Requires No Recharging And Integrates With Industry-Leading Continuous Glucose Monitors; Lowers FY26 Sales Guidance From $131M-$136M To $121M-$126M Reflecting Potential Revenue Deferral Impact Of Up To $10M In Q4 As New Prospective iLet Users Could Choose To Await The Launch Of Mint
Mint enables smartphone control for iOS and Android users. Mint is expected to meaningfully expand the Company’s addressable insulin delivery market, particularly among people with diabetes seeking a patch pump form
Senseonics Partners With Beta Bionics To Integrate Its Eversense 365 CGM With Beta Bionics’ iLet Bionic Pancreas Automated Insulin Delivery System
The companies are collaborating to integrate Eversense® 365 CGM with Beta Bionics’ iLet® Bionic Pancreas automated insulin delivery (AID) system designed to simplify diabetes management. The integrated device will aim
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-22 | Jones Christy | -6,430 | $23 | $147,890 |
| 2026-09-16 | Mensinger Mike | -2,650 | $22 | $58,300 |
| 2026-09-16 | Hopman Mark | -30,779 | $20.1319 | $619,640 |
| 2026-09-14 | Hopman Mark | -775 | $15.52 | $12,028 |
| 2026-09-09 | Hopman Mark | -36,870 | $18.4628 | $680,723 |
| 2026-09-09 | Hopman Mark | -35,994 | $18.4628 | $664,550 |
| 2026-09-03 | Saint Sean | -5,641 | $20.0778 | $113,259 |
| 2026-09-02 | Russell Steven Jon | -4,221 | $19.1131 | $80,676 |
| 2026-09-02 | Saint Sean | -16,867 | $19.1131 | $322,381 |
| 2026-09-02 | Feider Stephen | -6,675 | $19.1131 | $127,580 |
| 2026-09-02 | Mensinger Mike | -4,375 | $19.1131 | $83,620 |
| 2026-09-02 | Hopman Mark | -5,327 | $19.1131 | $101,815 |
| 2026-06-29 | Feider Stephen | -4,896 | - | - |
| 2026-06-29 | Feider Stephen | -4,896 | $17.0304 | $83,381 |
| 2026-06-29 | Feider Stephen | +4,896 | $5.1 | $24,970 |
| 2026-06-26 | Feider Stephen | -5,104 | - | - |
| 2026-06-26 | Feider Stephen | -5,104 | $17.0467 | $87,006 |
| 2026-06-26 | Feider Stephen | +5,104 | $5.1 | $26,030 |
| 2026-06-24 | Hopman Mark | -1,258 | $15.0083 | $18,880 |
| 2026-06-24 | Jones Christy | -1,406 | $15 | $21,090 |
| 2026-06-04 | Hopman Mark | -275 | $12.31 | $3,385 |
| 2026-06-04 | Jones Christy | -2,811 | $14 | $39,354 |
| 2026-06-02 | Russell Steven Jon | -4,222 | $12.6071 | $53,227 |
| 2026-06-02 | Saint Sean | -16,872 | $12.6071 | $212,707 |
| 2026-06-02 | Feider Stephen | -6,676 | $12.6071 | $84,165 |
| 2026-06-02 | Mensinger Mike | -4,378 | $12.6071 | $55,194 |
| 2026-06-02 | Hopman Mark | -5,329 | $12.6071 | $67,183 |
| 2026-05-22 | Lezack Adam | -998 | $11.21 | $11,188 |
| 2026-05-21 | Jones Christy | +16,965 | - | - |
| 2026-05-21 | Jones Christy | -1,998 | $9.95 | $19,880 |
| 2026-05-21 | Lezack Adam | +16,965 | - | - |
| 2026-05-21 | Lezack Adam | -1,000 | $9.95 | $9,950 |
| 2026-05-21 | Palasis Maria | +16,965 | - | - |
| 2026-05-21 | Dearen Danny L. | +16,965 | - | - |
| 2026-05-21 | CARNEY SEAN | +16,965 | - | - |
| 2026-05-21 | MICHEL GERARD J | +16,965 | - | - |
| 2026-03-04 | Hopman Mark | -353 | $11.57 | $4,084 |
| 2026-03-02 | Russell Steven Jon | -1,026 | $12.3616 | $12,683 |
| 2026-03-02 | Saint Sean | -3,384 | $12.3616 | $41,832 |
| 2026-03-02 | Feider Stephen | -1,428 | $12.3616 | $17,652 |
| 2026-03-02 | Mensinger Mike | -1,064 | $12.3616 | $13,153 |
| 2026-03-02 | Hopman Mark | -834 | $12.3616 | $10,310 |
| 2026-02-27 | Russell Steven Jon | +91,520 | - | - |
| 2026-02-27 | Saint Sean | +287,944 | - | - |
| 2026-02-27 | Feider Stephen | +110,342 | - | - |
| 2026-02-27 | Mensinger Mike | +91,520 | - | - |
| 2026-02-27 | Hopman Mark | +91,520 | - | - |
| 2026-02-27 | Russell Steven Jon | +58,749 | - | - |
| 2026-02-27 | Russell Steven Jon | +109,105 | - | - |
| 2026-02-27 | Saint Sean | +184,837 | - | - |
| 2026-02-27 | Saint Sean | +343,269 | - | - |
| 2026-02-27 | Feider Stephen | +70,831 | - | - |
| 2026-02-27 | Feider Stephen | +131,543 | - | - |
| 2026-02-27 | Mensinger Mike | +58,749 | - | - |
| 2026-02-27 | Mensinger Mike | +109,105 | - | - |
| 2026-02-27 | Hopman Mark | +58,749 | - | - |
| 2026-02-27 | Hopman Mark | +109,105 | - | - |
| 2026-01-13 | Jones Christy | +3,997 | - | - |
| 2026-01-13 | Lezack Adam | +3,997 | - | - |
| 2026-01-13 | Palasis Maria | +3,997 | - | - |
| 2026-01-13 | Dearen Danny L. | +3,997 | - | - |
| 2026-01-13 | CARNEY SEAN | +3,997 | - | - |
| 2026-01-13 | MICHEL GERARD J | +3,997 | - | - |
| 2026-01-06 | Mensinger Mike | -2,200 | $30.1005 | $66,221 |
| 2026-01-02 | Feider Stephen | -20,000 | - | - |
| 2026-01-02 | Feider Stephen | -20,000 | $29.534 | $590,680 |
| 2026-01-02 | Feider Stephen | +20,000 | $5.1 | $102,000 |
| 2026-01-02 | Mensinger Mike | -600 | $30.1969 | $18,118 |
| 2026-01-02 | Mensinger Mike | -7,200 | $29.56 | $212,832 |
| 2025-12-04 | Hopman Mark | -2,061 | $30.661 | $63,192 |
| 2025-12-02 | Russell Steven Jon | -1,025 | $29.3359 | $30,069 |
| 2025-12-02 | Hopman Mark | -856 | $29.3359 | $25,112 |
| 2025-12-02 | Saint Sean | -3,278 | $29.3359 | $96,163 |
| 2025-12-02 | Feider Stephen | -1,427 | $29.3359 | $41,862 |
| 2025-12-02 | Mensinger Mike | -1,063 | $29.3359 | $31,184 |
| 2025-12-01 | Lezack Adam | -500 | $29.91 | $14,955 |
| 2025-12-01 | Lezack Adam | -906 | $29.3463 | $26,588 |
| 2025-12-01 | Palasis Maria | -500 | $29.964 | $14,982 |
| 2025-12-01 | Palasis Maria | -906 | $29.3269 | $26,570 |
| 2025-10-31 | Lezack Adam | -38 | $27.7 | $1,053 |
| 2025-10-31 | Lezack Adam | -1,368 | $26.8474 | $36,727 |
| 2025-10-31 | Palasis Maria | -119 | $27.4502 | $3,267 |
| 2025-10-31 | Palasis Maria | -1,287 | $26.8588 | $34,567 |
| 2025-10-03 | Feider Stephen | -4,982 | - | - |
| 2025-10-03 | Feider Stephen | -1,154 | $22.2778 | $25,709 |
| 2025-10-03 | Feider Stephen | -3,828 | $21.5172 | $82,368 |
| 2025-10-03 | Feider Stephen | +4,982 | $5.1 | $25,408 |